glp-1 news employers The Remaining Gaps in Employer-Covered Benefits GLP-1 drug use nearly quadruples

The FDA also advises consumers to use state-licensed pharmacies when purchasing medications

Conclusions These findings inform and contextualize future studies assessing cardiorenal outcomes for these and additional treatments, including finerenone, for individuals with CKD and type 2 diabetes

If compounded GLP-1 drugs become unavailable, employers will face increased pressure to provide coverage for GLP-1 medications for their members who are obese overweight with a metabolic complication

If youre dealing with sulfur burps or any other concerns during your GLP-1 therapy, dont hesitate to reach out to our team for guidance and support

doi:10.1055/a-1608-0345 197